It is estimated that 1.3 million people in the U.S. will be diagnosed with cancer in 2003, and that 1 in 4 deaths will be due to the disease.  In the fight against cancer, which is the second-leading cause of death in the U.S. after heart disease, remarkable advancements have been made in developing sophisticated tools to detect malignancies at their earliest and most treatable stages.

In 2002, more than 172.5 million cancer screening and diagnostic procedures were performed utilizing imaging, in vitro diagnostic testing, and tissue biopsy methods.  These procedures generated approximately $2.7 billion in corresponding product sales, with oncology-related imaging system sales accounting for 53.5% of the total, imaging contrast agents and biopharmaceuticals for 20.4%, biomolecular cancer marker testing products for 11.6%, automated Pap smear preparation/screening systems for 9.1%, and minimally invasive biopsy devices for 5.4%.

This dynamic report from Medtech Insight includes analyses of products, technologies, current and forecast markets, competitors, and opportunities in the U.S. diagnostic oncology products market. 

Covered topics in this report include automated minimally invasive breast biopsy systems; automated Pap smear preparation/screening systems; biomolecular technologies for cancer detection and profiling; biomolecular cancer markers; cancer incidence, prevalence, and mortality statistics; computed tomography systems; conventional X-ray-based imaging systems; diagnostic ultrasound imaging systems; electrical impedance scanning; imaging contrast agents and radiopharmaceuticals; magnetic resonance imaging systems; mammography systems; near-infrared tomography; nuclear medicine imaging systems; opto-electronic spectroscopy; and site-specific cancer marker developments.

TABLE OF CONTENTS

EXECUTIVE SUMMARY

i.   Cancer Incidence, Prevalence, and Mortality in the United States

ii.   Diagnostic Oncology Procedures and Techniques

iii.  Diagnostic Oncology Products Markets

a.  Diagnostic Imaging Systems

b.  Imaging Contrast Agents and Radiopharmaceuticals

c.  Minimally Invasive Biopsy Systems

d.  Automated Papanicolaou Smear Preparation and Screening
Systems

e.  Biomolecular Cancer Marker Testing Products

1. CANCER ETIOLOGY AND EPIDEMIOLOGY

1.1 Causes of Cancer

1.2 Incidence and Prevalence of Cancer

1.3 The Cost of Cancer

1.4 Types of Cancer

1.4.1   Bladder Cancer

  1.4.1.1 Etiology

  1.4.1.2 Epidemiology

1.4.2   Brain/Nervous System Cancer

  1.4.2.1 Etiology

  1.4.2.2 Epidemiology

1.4.3   Breast Cancer

  1.4.3.1 Etiology

  1.4.3.2 Epidemiology

1.4.4   Colon/Rectal Cancer

  1.4.4.1 Etiology

  1.4.4.2 Epidemiology

1.4.5   Leukemia

  1.4.5.1 Etiology

  1.4.5.2 Epidemiology

1.4.6   Lung/Bronchus Cancer

  1.4.6.1 Etiology

  1.4.6.2 Epidemiology

1.4.7   Lymphoma

  1.4.7.1 Etiology

  1.4.7.2 Epidemiology

1.4.8   Malignant Melanoma

  1.4.8.1 Etiology

  1.4.8.2 Epidemiology

1.4.9   Oral Cavity and Oropharyngeal Cancer

  1.4.9.1 Etiology

  1.4.9.2 Epidemiology

1.4.10 Ovarian Cancer

  1.4.10.1 Etiology

  1.4.10.2 Epidemiology

1.4.11 Pancreatic Cancer

  1.4.11.1 Etiology

  1.4.11.2 Epidemiology

1.4.12 Prostate Cancer

  1.4.12.1 Etiology

  1.4.12.2 Epidemiology

1.4.13 Uterine/Cervical Cancer

  1.4.13.1 Etiology

  1.4.13.2 Epidemiology

2. DIAGNOSTIC ONCOLOGY PROCEDURES AND TECHNIQUES

2.1 In Vivo Diagnostic Imaging

2.1.1  Conventional X-Ray-Based Imaging

  2.1.1.1 X-Ray Contrast Media

  2.1.1.2 Conventional X-Ray-Based Imaging, Oncologic
   Applications

  2.1.1.3 Conventional X-Ray-Based Imaging, Procedure
   Volumes

  2.1.1.4 Mammography

   2.1.1.4.1 Digital Mammography

   2.1.1.4.2 Computer-Aided Detection in Mammography

   2.1.1.4.3 Mammography, Procedure Volumes

2.1.2  Computed Tomography

  2.1.2.1 Spiral Computed Tomography

  2.1.2.2 Electron Beam Computed Tomography

  2.1.2.3 Multislice Computed Tomography

  2.1.2.4 Computed Tomography, Oncologic Applications

  2.1.2.5 Computed Tomography, Procedure Volumes

2.1.3  Magnetic Resonance Imaging

  2.1.3.1 Functional Magnetic Resonance Imaging

  2.1.3.2 Interventional Magnetic Resonance

  2.1.3.3 Proton Magnetic Resonance Spectroscopy

  2.1.3.4 Magnetic Resonance Imaging Contrast Media

  2.1.3.5 Magnetic Resonance Imaging Techniques, Oncologic
   Applications

  2.1.3.6 Magnetic Resonance Imaging, Procedure Volumes

2.1.4  Nuclear Medicine Imaging

  2.1.4.1 Gamma Camera Imaging

  2.1.4.2 Positron Emission Tomography Imaging

  2.1.4.3 Radioimmunoscintigraphy

  2.1.4.4 Fusion Positron Emission Tomography/Computed
   Tomography Imaging Systems

  2.1.4.5 Nuclear Medicine Imaging, Oncologic Applications

  2.1.4.6 Nuclear Medicine Imaging, Procedure Volumes

2.1.5  Diagnostic Ultrasound Imaging

  2.1.5.1 Three-Dimensional Ultrasound

  2.1.5.2 Contrast-Enhanced Ultrasound

  2.1.5.3 Diagnostic Ultrasound, Oncologic Applications

  2.1.5.4 Diagnostic Ultrasound Imaging, Procedure Volumes

2.1.6  Emerging Application-Specific Imaging Techniques

2.1.6.1 Electrical Impedance Scanning

2.1.6.2 Near-Infrared Tomography

2.1.6.3 Opto-Electronic Spectroscopy

2.2 In Vitro Cancer Diagnostics

2.2.1  Tumor Tissue Biopsy

  2.2.1.1 Tissue Biopsy Methods

  2.2.1.2 Tissue Biopsy, Procedure Volumes

2.2.2  Biomolecular Cancer Markers

  2.2.2.1 Alpha-Fetoprotein

  2.2.2.2 Bladder Tumor-Associated Antigen

  2.2.2.3 Cancer Antigen 15-3

  2.2.2.4 Cancer Antigen 19-9

  2.2.2.5 Cancer Antigen 27-29

  2.2.2.6 Cancer Antigen 125

  2.2.2.7 Cancer-Associated Serum Antigen

  2.2.2.8 Carcinoembryonic Antigen

  2.2.2.9 Human Chorionic Gonadotropin-Beta

  2.2.2.10 Neuron-Specific Enolase

  2.2.2.11 Prostate-Specific Antigen

  2.2.2.12 Prostatic Acid Phosphatase

  2.2.2.13 Selected Breast Cancer Markers

  2.2.2.14 Selected Lung Cancer Markers

  2.2.2.15 Biomolecular Cancer Marker Testing, Procedure
    Volumes

2.2.3  Oncogenes and Tumor Suppressor Genes as Possible Cancer
  Markers

  2.2.3.1 Established and Emerging Genetic Cancer Markers

  2.2.3.2 Site-Specific Cancer Marker Developments

   2.2.3.2.1 Bladder Cancer

   2.2.3.2.2 Breast Cancer

   2.2.3.2.3 Colon/Rectal Cancer

   2.2.3.2.4 Esophageal Cancer

   2.2.3.2.5 Liver Cancer

   2.2.3.2.6 Lung/Bronchus Cancer

   2.2.3.2.7 Ovarian Cancer

   2.2.3.2.8 Pancreatic Cancer

   2.2.3.2.9 Prostate Cancer

   2.2.3.2.10 Telomerase-Based Universal Cancer
      Markers

  2.2.3.3 Advanced Biomolecular Technologies for Cancer
   Detection and Profiling

   2.2.3.3.1 Immunohistochemical Analysis

   2.2.3.3.2 Microarray Expression Analysis

   2.2.3.3.3 Polymerase Chain Reaction Technology

   2.2.3.3.4 Serial Analysis of Gene Expression

   2.2.3.3.5 Surface-Enhanced Laser
    Desorption/Ionization

  2.2.3.4 Cancer Chemosensitivity Testing

2.2.4  Traditional Cancer Screening Tests

  2.2.4.1 Colon/Rectal Cancer Screening

  2.2.4.2 Helicobacter Pylori Testing

  2.2.4.3 Human Papillomavirus Testing

  2.2.4.4 The Papanicolaou Test

  2.2.4.5 Cancer Screening Tests, Procedure Volumes

3. DIAGNOSTIC ONCOLOGY PRODUCTS MARKETS

3.1 Diagnostic Imaging Platforms

3.1.1  Conventional X-Ray-Based Imaging Systems

  3.1.1.1 Products

  3.1.1.2 Conventional X-Ray-Based Imaging Systems, Market
   Forecast

  3.1.1.3 Conventional X-Ray-Based Imaging Systems,
   Competitive Analysis

3.1.2  Mammography Systems

  3.1.2.1 Products

  3.1.2.2 Mammography Systems, Market Forecast

  3.1.2.3 Mammography Systems, Competitive Analysis

3.1.3  Computed Tomography Systems

  3.1.3.1 Products

  3.1.3.2 Market Forecast

  3.1.3.3 Competitive Analysis

3.1.4  Magnetic Resonance Imaging Systems

  3.1.4.1 Products

  3.1.4.2 Market Forecast

  3.1.4.3 Competitive Analysis

3.1.5  Nuclear Medicine Imaging Systems

  3.1.5.1 Products

  3.1.5.2 Market Forecast

  3.1.5.3 Competitive Analysis

3.1.6  Ultrasound Imaging Systems

  3.1.6.1 Products

  3.1.6.2 Market Forecast

  3.1.6.3 Competitive Analysis

3.2 Imaging Contrast Agents and Radiopharmaceuticals

3.2.1  X-Ray Contrast Media

  3.2.1.1 Products

  3.2.1.2 Market Forecast

  3.2.1.3 Competitive Analysis

3.2.2  Magnetic Resonance Imaging Contrast Media

  3.2.2.1 Products

  3.2.2.2 Market Forecast

  3.2.2.3 Competitive Analysis

3.2.3  Nuclear Medicine Radiopharmaceuticals

  3.2.3.1 Products

  3.2.3.2 Market Forecast

  3.2.3.3 Competitive Analysis

3.3 Minimally Invasive Biopsy Systems

3.3.1  Automated Minimally Invasive Breast Biopsy Systems

  3.3.1.1 Products

  3.3.1.2 Market Forecast

  3.3.1.3 Competitive Analysis

3.3.2  Core Biopsy Needle Devices

  3.3.2.1 Products

  3.3.2.2 Market Forecast

  3.3.2.3 Competitive Analysis

3.4 Automated Papanicolaou Smear Preparation and Screening Systems

3.4.1  Products

3.4.2  Market Forecast

3.4.3  Competitive Analysis

3.5 Biomolecular Cancer Marker Testing Products

3.5.1  Products

3.5.2  Market Forecast

3.5.3  Competitive Analysis

4. COMPANY PROFILES

4.1   Abbott Laboratories

4.2   Amersham Group

4.3   C.R. Bard, Inc.

4.4   Bayer AG

4.5   Berlex Laboratories, Inc./Schering AG

4.6   Bracco Diagnostics, Inc./Bracco Group

4.7   Bristol-Myers Squibb Company

4.8   Cytyc Corporation

4.9   Digene Corporation

4.10 Ethicon Endo-Surgery, Inc./Johnson & Johnson

4.11 Fischer Imaging Corporation

4.12 GE Medical Systems, Inc./General Electric Company

4.13 Hologic, Inc.

4.14 Mallinckrodt Imaging/Tyco International LTD

4.15 Myriad Genetics, Inc.

4.16 Nuclear Pharmacy Services/Cardinal Health, Inc.

4.17 Philips Medical Systems/Royal Philips Electronics NV

4.18 R2 Technology, Inc.

4.19 Siemens Medical Solutions/Siemens AG

APPENDIX:  COMPANY LISTING   

LIST OF EXHIBITS

Exhibit ES-1:    2002, Cancer Incidence, Prevalence, and Mortality, by Site

Exhibit ES-2:    Diagnostic Oncology, Procedure Volumes Forecast, 2002-2007

Exhibit ES-3:    Diagnostic Oncology Products, Market Forecast, 2002-2007

Exhibit ES-4:    Diagnostic Imaging Systems, Market Forecast, 2002-2007

Exhibit ES-5:    Contrast-Enhanced Diagnostic Oncology Imaging, Procedure Volumes Forecast, 2002-2007

Exhibit ES-6:    Oncology-Related Imaging Contrast Agents and Radiopharmaceuticals, Market Forecast, 2002-2007

Exhibit ES-7:    Oncology-Related Minimally Invasive Tissue Biopsy, Procedure Volumes Forecast, 2002-2007

Exhibit ES-8:    Oncology-Related Minimally Invasive Tissue Biopsy Systems, Market Forecast, 2002-2007

Exhibit ES-9:    Automated Papanicolaou Smear Preparation and Screening Systems, Market Forecast, 2002-2007

Exhibit ES-10:   Biomolecular Cancer Marker Testing Products, Market Forecast, 2002-2007

Exhibit 1-1:      2002, Cancer Incidence, Prevalence, and Mortality, by Site

Exhibit 1-2:      2002, Bladder Cancer, Facts and Figures

Exhibit 1-3:      2002, Brain Cancer, Facts And Figures

Exhibit 1-4:      2002, Breast Cancer, Facts And Figures

Exhibit 1-5:      2002, Colon/Rectal Cancer, Facts And Figures

Exhibit 1-6:      2002, Leukemia, Facts and Figures

Exhibit 1-7:      2002, Lung/Bronchus Cancer, Facts And Figures

Exhibit 1-8:      2002, Lymphoma, Facts and Figures

Exhibit 1-9:      2002, Malignant Melanoma, Facts and Figures

Exhibit 1-10:     2002, Oral Cavity and Oropharyngeal Cancer, Facts and Figures

Exhibit 1-11:     2002, Ovarian Cancer, Facts and Figures

Exhibit 1-12:     2002, Pancreatic Cancer, Fact and Figures

Exhibit 1-13:     2002, Prostate Cancer, Facts And Figures

Exhibit 1-14:     2002, Uterine/Cervical Cancer, Facts and Figures

Exhibit 2-1:      Diagnostic Oncology, Procedure Volumes Forecast, 2002-2007

Exhibit 2-2:      Oncology-Related Conventional X-Ray-Based Imaging, Procedure Volumes Forecast, 2002-2007

Exhibit 2-3:      Mammography, Procedure Volumes Forecast, 2002-2007

Exhibit 2-4:      Oncology-Related Computed Tomography, Procedure Volumes Forecast, 2002-2007

Exhibit 2-5:      Oncology-Related Magnetic Resonance Imaging, Procedure Volumes Forecast, 2002-2007

Exhibit 2-6:      Oncology-Related Nuclear Medicine Imaging, Procedure Volumes Forecast, 2002-2007

Exhibit 2-7:      Oncology-Related Diagnostic Ultrasound, Procedure Volumes Forecast, 2002-2007

Exhibit 2-8:      Oncology-Related Tissue Biopsy, Procedure Volumes Forecast, 2002-2007

Exhibit 2-9:      2003, Selected Biomolecular Tumor Markers

Exhibit 2-10:     Biomolecular Cancer Marker Testing, Procedure Volumes Forecast, 2002-2007

Exhibit 2-11:     2003, Emerging and Established Genetic Markers for Diagnostic Oncology Applications

Exhibit 2-12:     Selected Cancer Screening Tests, Procedure Volumes Forecast, 2002-2007

Exhibit 3-1:      Oncology-Related Diagnostic Examinations, Procedure Volumes Forecast, 2002-2007

Exhibit 3-2:      Diagnostic Oncology Products, Market Forecast, 2002-2007

Exhibit 3-3:      Diagnostic Imaging Systems, Market Forecast, 2002-2007

Exhibit 3-4:      2003, Selected Conventional X-Ray-Based Imaging Systems

Exhibit 3-5:      Conventional X-Ray-Based Imaging Systems, Market Forecast, 2002-2007

Exhibit 3-6:      2002, Conventional X-Ray-Based Imaging Systems Market, Share by Supplier

Exhibit 3-7:      2003, Selected Mammography Systems

Exhibit 3-8:      Mammography Systems, Market Forecast, 2002-2007

Exhibit 3-9:      2002, Mammography Systems Market, Share by Supplier

Exhibit 3-10:     2003, Selected Computed Tomography Systems

Exhibit 3-11:     Computed Tomography Systems, Market Forecast, 2002-2007

Exhibit 3-12:     2002, Computed Tomography Systems Market, Share by Supplier

Exhibit 3-13:     2003, Selected Magnetic Resonance Imaging Systems

Exhibit 3-14:     Magnetic Resonance Imaging Systems, Market Forecast, 2002-2007

Exhibit 3-15:     2002, Magnetic Resonance Imaging Systems Market, Share by Supplier

Exhibit 3-16:     2003, Selected Nuclear Medicine Imaging Systems

Exhibit 3-17:     Nuclear Medicine Imaging Systems, Market Forecast, 2002-2007

Exhibit 3-18:     2002, Nuclear Medicine Imaging Systems Market, Share by Supplier

Exhibit 3-19:     2003, Selected Diagnostic Ultrasound Imaging Systems

Exhibit 3-20:     Diagnostic Ultrasound Imaging Systems, Market Forecast, 2002-2007

Exhibit 3-21:     2002, Diagnostic Ultrasound Imaging Systems Market, Share by Supplier

Exhibit 3-22:     Contrast-Enhanced Diagnostic Oncology Imaging, Procedure Volumes Forecast, 2002-2007

Exhibit 3-23:     Oncology-Related Imaging Contrast Agents and Radiopharmaceuticals, Market Forecast, 2002-2007

Exhibit 3-24:     Oncology-Related Conventional X-Ray and Computed Tomography Imaging Contrast Agents, Market Forecast, 2002-2007

Exhibit 3-25:     2002, Oncology-Related Conventional X-Ray and Computed Tomography Imaging Contrast Agents Market, Share by Supplier

Exhibit 3-26:     Oncology-Related Magnetic Resonance Imaging Contrast Media, Market Forecast, 2002-2007

Exhibit 3-27:     2002, Oncology-Related Magnetic Resonance Imaging Contrast Media Market, Share by Supplier

Exhibit 3-28:     Oncology-Related Nuclear Medicine Imaging Radiopharmaceuticals, Market Forecast, 2002-2007

Exhibit 3-29:     2002, Oncology-Related Nuclear Medicine Imaging Radiopharmaceuticals Market, Share by Supplier

Exhibit 3-30:     Oncology-Related Minimally Invasive Tissue Biopsy, Procedure Volumes Forecast, 2002-2007

Exhibit 3-31:     Oncology-Related Minimally Invasive Tissue Biopsy Systems, Market Forecast, 2002-2007

Exhibit 3-32:     Automated Breast Biopsy Systems, Market Forecast, 2002-2007

Exhibit 3-33:     2002, Automated Breast Biopsy Systems Market, Share by Supplier

Exhibit 3-34:     Oncology-Related Core Biopsy Needle Products, Market Forecast, 2002-2007

Exhibit 3-35:     2002, Oncology-Related Core Biopsy Needle Products Market, Share by Supplier

Exhibit 3-36:     Automated Papanicolaou Smear Preparation and Screening Systems, Market Forecast, 2002-2007

Exhibit 3-37:     2002, Automated Papanicolaou Smear Preparation and Screening Systems Market, Share by Supplier

Exhibit 3-38:     Biomolecular Cancer Marker Testing Products, Market Forecast, 2002-2007

Exhibit 3-39:     2002, Biomolecular Cancer Marker Testing Products Market, Share by Supplier

Copyright 2003, Medtech Insight, LLC